Gilead’s newly approved drug Complera, the Second Triple Combination Once-a-Day Pill Intended for Untreated HIV Patients

Date: August 1, 2011
Pages: 5
Price:
US$ 500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G25485CC467EN
Leaflet:

Download PDF Leaflet

Gilead’s newly approved drug Complera, the Second Triple Combination Once-a-Day Pill Intended for Untreated HIV Patients
Gilead’s newly approved drug Complera, the Second Triple Combination Once-a-Day Pill Intended for Untreated HIV Patients is unlikely to displace its own market-leading drug, Atripla

Summary

GlobalData’s viewpoint, “Gilead’s newly approved drug Complera, the Second Triple Combination Once-a-Day Pill Intended for Untreated HIV Patients is unlikely to displace its own market-leading drug, Atripla” is a featured article highlighting the discovery of the Complera and its added benefits from its own market-leading drug, Atripla. This report features the current therapeutics available in HIV therapy.

Scope
  • This report depicts expectations for long-term market growth are for Complera and primary reasons
Reasons to buy
  • Understand the limitations of currently marketed drugs in HIV therapy and the growing importance of combination therapies in the treatment of HIV Identify opportunities and devise pipeline strategies to suit current market requirements
1 TABLE OF CONTENTS2 SUMMARY3 HIV-1

3.1 Disease Overview
3.2 Management of HIV

4 UNMET NEED5 APPROVAL OF COMPLERA FOR THE TREATMENT OF HIV-1

5.1 Clinical Trials
5.2 ECHO and THRIVE
5.3 Dosing and Pricing of Complera

6 MARKET DYNAMICS

6.1 Market Drivers
6.2 Market Restraints

7 APPENDIX

7.1 Methodology
  7.1.1 Coverage
  7.1.2 Secondary Research
  7.1.3 Primary Research
  7.1.4 Expert Panel Validation
7.2 Contact Us
7.3 Disclaimer

Ask Your Question

Gilead’s newly approved drug Complera, the Second Triple Combination Once-a-Day Pill Intended for Untreated HIV Patients
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: